• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Phe (c.659A>T); Zygosity=Unspecified (PubMed=21912889).
  

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H
Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
Eur. J. Cancer 31A:230-237(1995)

PubMed=19493612; DOI=10.1016/j.canlet.2009.05.010
Ramachandran A., Marshall E.S., Love D.R., Baguley B.C., Shelling A.N.
Activin is a potent growth suppressor of epithelial ovarian cancer cells.
Cancer Lett. 285:157-165(2009)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)